EICHORCondition: Urticaria · Sponsor: UCB Pharma
Study to Compare the Efficacy and Safety Between Levocetirizine and Loratadine for Chronic Idiopathic Urticaria.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Male or female, 18 to 60 years old (inclusive * having chronic idiopathic urticaria * at least 6-weeks history of CIU, had at least 3 days of wheals presence/week * moderate to severe CIU defined as pruritus score ≥ 2, number of wheals ≥ 2, and total symptoms CIU score ≥ 2 at randomization Exclusion Criteria: * Asthma requiring daily drug therapy other than ß2 inhaled agonists taken prn * atopic dermatitis or urticaria requiring an antihistamine treatment or the administration of oral or dermal topical corticosteroids * urticaria caused by physical factors or other known factors * cholinergic urticaria * had urticaria due to other systemic disorders * were on antihistamine drug currently
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Locations not yet listed on the registry record. |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT00525382